CryoPort, Inc. (NASDAQ:CYRX) CEO Jerrell Shelton Sells 16,344 Shares

CryoPort, Inc. (NASDAQ:CYRX - Get Free Report) CEO Jerrell Shelton sold 16,344 shares of CryoPort stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $7.06, for a total value of $115,388.64. Following the sale, the chief executive officer now directly owns 912,419 shares of the company's stock, valued at $6,441,678.14. This trade represents a 1.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Jerrell Shelton also recently made the following trade(s):

• On Tuesday, June 17th, Jerrell Shelton sold 151,304 shares of CryoPort stock. The stock was sold at an average price of $6.81, for a total transaction of $1,030,380.24.
• On Wednesday, June 18th, Jerrell Shelton sold 119,281 shares of CryoPort stock. The shares were sold at an average price of $6.81, for a total transaction of $812,303.61.
• On Friday, June 20th, Jerrell Shelton sold 69,135 shares of CryoPort stock. The stock was sold at an average price of $6.47, for a total transaction of $447,303.45.

CryoPort Price Performance

Shares of CryoPort stock traded up $0.15 during trading hours on Thursday, reaching $7.29. The stock had a trading volume of 299,675 shares, compared to its average volume of 518,676. The stock's 50 day moving average is $6.29 and its 200 day moving average is $6.70. The company has a current ratio of 5.56, a quick ratio of 5.24 and a debt-to-equity ratio of 0.51. CryoPort, Inc. has a twelve month low of $4.58 and a twelve month high of $9.78. The firm has a market capitalization of $365.52 million, a PE ratio of -3.12 and a beta of 1.85.

CryoPort (NASDAQ:CYRX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.01. The firm had revenue of $41.04 million during the quarter, compared to analyst estimates of $56.19 million. CryoPort had a negative return on equity of 11.03% and a negative net margin of 50.15%. Equities analysts expect that CryoPort, Inc. will post -0.99 earnings per share for the current fiscal year.

Analysts Set New Price Targets

CYRX has been the subject of a number of research reports. Guggenheim restated a "buy" rating and set a $10.00 target price on shares of CryoPort in a research report on Wednesday, April 16th. Roth Mkm reiterated a "buy" rating and set a $15.00 price objective on shares of CryoPort in a research note on Tuesday, April 1st. Morgan Stanley lowered their target price on CryoPort from $8.00 to $7.00 and set an "equal weight" rating on the stock in a research note on Monday, May 5th. Needham & Company LLC reaffirmed a "buy" rating and set a $11.00 target price on shares of CryoPort in a report on Thursday, May 8th. Finally, UBS Group boosted their price target on CryoPort from $10.00 to $11.00 and gave the company a "buy" rating in a report on Tuesday, April 1st. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $11.00.

Institutional Trading of CryoPort

Institutional investors and hedge funds have recently made changes to their positions in the business. Rhumbline Advisers grew its stake in CryoPort by 23.8% in the 1st quarter. Rhumbline Advisers now owns 78,320 shares of the company's stock valued at $476,000 after acquiring an additional 15,036 shares during the period. Graham Capital Management L.P. raised its position in CryoPort by 24.9% during the fourth quarter. Graham Capital Management L.P. now owns 28,460 shares of the company's stock worth $221,000 after acquiring an additional 5,667 shares during the period. Lazard Asset Management LLC purchased a new position in CryoPort during the fourth quarter valued at $51,000. ProShare Advisors LLC acquired a new stake in shares of CryoPort in the fourth quarter valued at about $95,000. Finally, Price T Rowe Associates Inc. MD grew its position in shares of CryoPort by 8.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 60,003 shares of the company's stock valued at $467,000 after purchasing an additional 4,902 shares during the period. 92.90% of the stock is currently owned by hedge funds and other institutional investors.

About CryoPort

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.